Skip to main content
Top
Published in: Pathology & Oncology Research 2/2020

01-04-2020 | Melanoma | Original Article

Immunohistochemical Staining in the Assessment of Melanoma Tumor Thickness

Authors: Kambiz Kamyab-Hesary, Alireza Ghanadan, Kamran Balighi, Seyede Faeze Mousavinia, Maryam Nasimi

Published in: Pathology & Oncology Research | Issue 2/2020

Login to get access

Abstract

Vertical tumor thickness has great influence in the prognosis and staging of melanoma. The aim of this study was determination of the differences between melanoma tumor thickness in conventional hematoxylin and eosin (H&E) and immunohistochemical techniques. Thirty-six biopsy specimens were included in our study. For each sample, four adjacent tissue sections were stained with H&E, in addition S-100, Melan- A and HMB-45 staining was performed on the next serial sections. The mean thickness of tumor invasion was 2.16, 2.38, 2.22 and 2.29 mm in H&E, S-100, HMB45 and Melan-A sections evaluation, respectively. The mean difference of the Breslow thickness between H&E and S-100 and also, between H&E and Melan-A stained slides were statistically significant (p˂0.05) while no difference was found in the tumor thickness of the H&E and HMB45 staining evaluation (p = 0.278). Greater tumor thickness was observed in 25 lesions (69.4%) with S-100, 20 lesions (55.5%) with Melan-A and 17 (47.2%) lesions in HMB-45 rather than H&E staining. Conclusively, it appears that H&E staining cannot prove the actual size of melanoma invasion in some cases and immunohistochemical examination can be a complementary method in this situations. Of the melanoma associated immunomarkers, the combination of S-100 and Melan-A staining may suffice to measure depth of tumor invasion.
Literature
1.
go back to reference Breslow A (1980) Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment. Pathol Annu 15:1–22PubMed Breslow A (1980) Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment. Pathol Annu 15:1–22PubMed
2.
go back to reference Shaikh WR, Dusza SW, Weinstock MA et al (2015) Melanoma thickness and survival trends in the United States, 1989–2009. J Natl Cancer Inst 12:108(1) Shaikh WR, Dusza SW, Weinstock MA et al (2015) Melanoma thickness and survival trends in the United States, 1989–2009. J Natl Cancer Inst 12:108(1)
3.
go back to reference Scolyer RA, Shaw HM, Thompson JF, Li LXL, Colman MH, Lo SK, McCarthy SW, Palmer AA, Nicoll KD, Dutta B, Slobedman E, Watson GF, Stretch JR (2003) Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol 27:1571–1576CrossRef Scolyer RA, Shaw HM, Thompson JF, Li LXL, Colman MH, Lo SK, McCarthy SW, Palmer AA, Nicoll KD, Dutta B, Slobedman E, Watson GF, Stretch JR (2003) Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol 27:1571–1576CrossRef
4.
go back to reference Haydu LE, Stollman JT, Scolyer RA, Spillane AJ, Quinn MJ, Saw RPM, Shannon KF, Stretch JR, Bonenkamp JJ, Thompson JF (2016) Minimum safe pathologic excision margins for primary cutaneous melanomas (1–2 mm in thickness): analysis of 2131 patients treated at a single center. Ann Surg Oncol 23:1071–1081CrossRef Haydu LE, Stollman JT, Scolyer RA, Spillane AJ, Quinn MJ, Saw RPM, Shannon KF, Stretch JR, Bonenkamp JJ, Thompson JF (2016) Minimum safe pathologic excision margins for primary cutaneous melanomas (1–2 mm in thickness): analysis of 2131 patients treated at a single center. Ann Surg Oncol 23:1071–1081CrossRef
5.
go back to reference Hurt MA, Santa Cruz DJ (1994) Malignant melanoma microstaging. History, premises, methods, problems, and recommendations—a call for standardization. Pathol Annu 29:51–74PubMed Hurt MA, Santa Cruz DJ (1994) Malignant melanoma microstaging. History, premises, methods, problems, and recommendations—a call for standardization. Pathol Annu 29:51–74PubMed
6.
go back to reference Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW (2008) Immunohistochemical characteristics of melanoma. J Cutan Pathol 35:433–444CrossRef Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW (2008) Immunohistochemical characteristics of melanoma. J Cutan Pathol 35:433–444CrossRef
7.
go back to reference Plaza JA, Suster D, Perez-Montiel D (2007) Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique. Appl Immunohistochem Mol Morphol 15:421–425CrossRef Plaza JA, Suster D, Perez-Montiel D (2007) Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique. Appl Immunohistochem Mol Morphol 15:421–425CrossRef
8.
go back to reference Paradela S, Fonseca E, Pita S, Kantrow SM, Goncharuk VN, Diwan H, Prieto VG (2009) Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool. J Cutan Pathol 36:740–752CrossRef Paradela S, Fonseca E, Pita S, Kantrow SM, Goncharuk VN, Diwan H, Prieto VG (2009) Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool. J Cutan Pathol 36:740–752CrossRef
9.
go back to reference Buzaid AC, Gershenwald JE, Atkins MB, Ross ME (2016) Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma. UpToDate. UpToDate, Waltham Buzaid AC, Gershenwald JE, Atkins MB, Ross ME (2016) Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma. UpToDate. UpToDate, Waltham
10.
go back to reference Drabeni M, Lopez-Vilaró L, Barranco C, Trevisan G, Gallardo F, Pujol RM (2013) Differences in tumor thickness between hematoxylin and eosin and Melan-A immunohistochemically stained primary cutaneous melanomas. Am J Dermatopathol 35:56–63CrossRef Drabeni M, Lopez-Vilaró L, Barranco C, Trevisan G, Gallardo F, Pujol RM (2013) Differences in tumor thickness between hematoxylin and eosin and Melan-A immunohistochemically stained primary cutaneous melanomas. Am J Dermatopathol 35:56–63CrossRef
11.
go back to reference Xia J, Wang Y, Li F, Wang J, Mu Y, Mei X, Li X, Zhu W, Jin X, Yu K (2016) Expression of microphthalmia transcription factor, S100 protein, and HMB-45 in malignant melanoma and pigmented nevi. Biomed Rep 5:327–331CrossRef Xia J, Wang Y, Li F, Wang J, Mu Y, Mei X, Li X, Zhu W, Jin X, Yu K (2016) Expression of microphthalmia transcription factor, S100 protein, and HMB-45 in malignant melanoma and pigmented nevi. Biomed Rep 5:327–331CrossRef
12.
go back to reference Orchard GE (1998) Melan A (MART-1): a new monoclonal antibody for malignant melanoma diagnosis. Br J Biomed Sci 55:8–9PubMed Orchard GE (1998) Melan A (MART-1): a new monoclonal antibody for malignant melanoma diagnosis. Br J Biomed Sci 55:8–9PubMed
13.
go back to reference Morton DL, Davtyan DG, Wanek LA, Foshag LJ, Cochran AJ (1993) Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer. 71:3737–3743CrossRef Morton DL, Davtyan DG, Wanek LA, Foshag LJ, Cochran AJ (1993) Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer. 71:3737–3743CrossRef
14.
go back to reference Urist MM, Balch CM, Soong SJ et al (1984) Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg 200:769–775CrossRef Urist MM, Balch CM, Soong SJ et al (1984) Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg 200:769–775CrossRef
15.
go back to reference Dyson SW, Bass J, Pomeranz J, Jaworsky C, Sigel J, Somach S (2005) Impact of thorough block sampling in the histologic evaluation of melanomas. Arch Dermatol 141:734–736CrossRef Dyson SW, Bass J, Pomeranz J, Jaworsky C, Sigel J, Somach S (2005) Impact of thorough block sampling in the histologic evaluation of melanomas. Arch Dermatol 141:734–736CrossRef
16.
go back to reference de Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Bröcker EB, Renard N, Eggermont AMM, van Muijen GNP, Ruiter DJ (2001) Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC melanoma cooperative group. J Pathol 193:13–20CrossRef de Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Bröcker EB, Renard N, Eggermont AMM, van Muijen GNP, Ruiter DJ (2001) Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC melanoma cooperative group. J Pathol 193:13–20CrossRef
17.
go back to reference Kim RH, Meehan SA (2017) Immunostain use in the diagnosis of melanomas referred to a tertiary medical center: a 15-year retrospective review (2001–2015). J Cutan Pathol 44:221–227CrossRef Kim RH, Meehan SA (2017) Immunostain use in the diagnosis of melanomas referred to a tertiary medical center: a 15-year retrospective review (2001–2015). J Cutan Pathol 44:221–227CrossRef
18.
go back to reference Penneys NS (1987) Microinvasive lentigo maligna melanoma. J Am Acad Dermatol 17:675–680CrossRef Penneys NS (1987) Microinvasive lentigo maligna melanoma. J Am Acad Dermatol 17:675–680CrossRef
19.
go back to reference Flügge G, Rassner G (1989) Demonstration of S 100 protein in malignant melanoma of the skin. Pattern of distribution and significance for determination of tumor thickness. Hautarzt. 40:290–295PubMed Flügge G, Rassner G (1989) Demonstration of S 100 protein in malignant melanoma of the skin. Pattern of distribution and significance for determination of tumor thickness. Hautarzt. 40:290–295PubMed
20.
go back to reference Prade M, Sancho-Garnier H, Cesarini JP, Cochran A (1980) Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int J Cancer 26:159–163CrossRef Prade M, Sancho-Garnier H, Cesarini JP, Cochran A (1980) Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int J Cancer 26:159–163CrossRef
21.
go back to reference Prieto VG, Shea CR (2008) Use of immunohistochemistry in melanocytic lesions. J Cutan Pathol 35:1–10CrossRef Prieto VG, Shea CR (2008) Use of immunohistochemistry in melanocytic lesions. J Cutan Pathol 35:1–10CrossRef
22.
go back to reference Megahed M, Schön M, Selimovic D, Schön MP (2002) Reliability of diagnosis of melanoma in situ. Lancet. 359:1921–1922CrossRef Megahed M, Schön M, Selimovic D, Schön MP (2002) Reliability of diagnosis of melanoma in situ. Lancet. 359:1921–1922CrossRef
23.
go back to reference Thum C, Hollowood K, Birch J, Goodlad JR, Brenn T (2011) Aberrant Melan-a expression in atypical fibroxanthoma and undifferentiated pleomorphic sarcoma of the skin. J Cutan Pathol 38:954–960CrossRef Thum C, Hollowood K, Birch J, Goodlad JR, Brenn T (2011) Aberrant Melan-a expression in atypical fibroxanthoma and undifferentiated pleomorphic sarcoma of the skin. J Cutan Pathol 38:954–960CrossRef
24.
go back to reference Bax MJ, Johnson TM, Harms PW, Schwartz JL, Zhao L, Fullen DR, Chan MP (2016) Detection of occult invasion in melanoma in situ. JAMA Dermatol 152:1201–1208CrossRef Bax MJ, Johnson TM, Harms PW, Schwartz JL, Zhao L, Fullen DR, Chan MP (2016) Detection of occult invasion in melanoma in situ. JAMA Dermatol 152:1201–1208CrossRef
25.
go back to reference Kim J, Taube J, McCalmont TH, Glusac EJ (2011) Quantitative comparison of MiTF, Melan-a, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. J Cutan Pathol 38:775–779CrossRef Kim J, Taube J, McCalmont TH, Glusac EJ (2011) Quantitative comparison of MiTF, Melan-a, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. J Cutan Pathol 38:775–779CrossRef
26.
go back to reference Helm TN, Helm KF (2014) Breslow thickness determined with the use of Immunohistochemical techniques could provide misleading information when used with prognostic models based on data obtained by conventional means. Am J Dermatopathol 36:757CrossRef Helm TN, Helm KF (2014) Breslow thickness determined with the use of Immunohistochemical techniques could provide misleading information when used with prognostic models based on data obtained by conventional means. Am J Dermatopathol 36:757CrossRef
Metadata
Title
Immunohistochemical Staining in the Assessment of Melanoma Tumor Thickness
Authors
Kambiz Kamyab-Hesary
Alireza Ghanadan
Kamran Balighi
Seyede Faeze Mousavinia
Maryam Nasimi
Publication date
01-04-2020
Publisher
Springer Netherlands
Keywords
Melanoma
Melanoma
Published in
Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00635-y

Other articles of this Issue 2/2020

Pathology & Oncology Research 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine